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doses of lithium or valproate. Although further investigations are necessary, our results show the neuroprotective effect of
lithium and valproate against neural cell death induced by extracellular ATP, probably through a different pathway, and
suggest novel uses of these drugs in neurodegenerative diseases.
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An increasing number of studies indicate that glial cells, in both sensory ganglia and in the central nervous system, play an
important role in the generation and maintenance of pathological pain. In sensory ganglia, satellite glial cells envelop the
cell bodies of primary sensory neurons forming a morphological and functional unit, allowing a non-synaptic cell-to-cell
communication. Among the various pain mediators that contribute to neuron-to-glia signaling within sensory ganglia (i.e.,
SP, CGRP, bradykinin), adenine and uracil nucleotides acting via the P2X and P2Y receptors represent a relatively new and
interesting class of molecules. It is now widely accepted that the P2X3 channel plays a fundamental role in ATP-mediated
painful signals. However, evidence is emerging that P2Y receptors may also participate to pain [1]. We are currently
studying the role of these receptors in cell-to-cell communication in trigeminal ganglia, an important station for pain
maintenance and integration in various painful situations, including migraine. We have previously reported the presence of
functional neuronal P2X3 as well as of ADP-sensitive P2Y1,12,13 and UTP-activated P2Y2/P2Y4 receptors in mixed primary
trigeminal cultures on both neurons and glia. Moreover, a chronic exposure (i.e., 24 h) to the algogen bradykinin (BK,
100 nM) significantly enhanced the functionality of glial P2Y1,2,4 receptor subtypes [2]. Since in our model BK receptors
are functional on neurons only, we hypothesized that BK is able to stimulate the neuronal release of a chemical mediator
which can, in turn, increase P2Y receptor activity on glial cells. Our results suggest this mediator to be CGRP because (1)
this peptide is extracellularly released by BK, (2) exogenously added CGRP fully mimics the BK-mediated potentiation of
P2Y receptor function, and (3) the CGRP antagonist CGRP8-37 completely prevents BK-mediated effects. Application of
CGRP led to the activation of the ERK 1/2 signaling pathway, which could be then linked to P2Y receptor potentiation.
Taken together, our data indicate that P2Y receptors may significantly participate to neuron-to-glia communication in
trigeminal ganglia and that they can be modulated by algogens released during chronic pain states. Therefore, we believe
that P2Y receptors might represent new potential therapeutic targets for the development of innovative analgesic drugs,
especially for migraine.
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